Phaseline

Targets › BTK

BTK (Tyrosine-protein kinase BTK): drug programs, companies and trials

30 programs from 26 companies in 402 trials: 249 Phase 2, 75 Phase 3, 71 Phase 1, 7 Phase 4; Oncology, Neurology, Other; next expected readout Nov 2026.

Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. (UniProt, Q06187)

Open in Phaseline: the race on BTK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaAcalabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 4Chronic Lymphocytic Leukaemia; Untreated Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; Mantle-cell Lymphoma …Jan 2027
Eli LillyPirtobrutinib (LY3527727)
Tyrosine-protein kinase BTK inhibitor
BTKPhase 4Chronic Lymphocytic Leukemia; Lymphoma, Non-Hodgkin; Immune Thrombocytopenia (ITP)Feb 2028
Sanofirilzabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Immune Thrombocytopenia; Sickle Cell Disease; Autoimmune Haemolytic Anaemia; Immunoglobulin G4 Related Disease …Nov 2026
BeOne MedicinesZanubrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3B-cell Malignancies; Relapsed/Refractory Follicular Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Non-Hodgkin Lymphoma …Nov 2026
Dizal PharmaceuticalsDZD8586 (Birelentinib)
Birelentinib; BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Immune Thrombocytopenia (ITP); Healthy; Diffuse Large B-Cell LymphomaNov 2026
BeOne MedicinesTacabrutideg (BGB-16673)
BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; CLL; Chronic Spontaneous Urticaria; B-cell MalignancyNov 2026
Acerta PharmaAcalabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; Lymphoma, Mantle Cell; Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma (MCL) …Dec 2026
Johnson & Johnson (Janssen)Ibrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Anemia; Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type …Dec 2026
Nurix TherapeuticsNX-5948
Non-covalent BTK inhibitor
BTKPhase 3B-cell Lymphoma; Chronic Lymphocytic Leukemia (CLL)Jan 2027
Merck & Co. (MSD)Nemtabrutinib (MK-1026)
Bruton's tyrosine kinase inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Hematologic Malignancies; Severe Renal Impairment …Feb 2027
Novartisremibrutinib (LOU064)
Bruton's tyrosine kinase (BTK) inhibitor
BTKPhase 3Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa; Chronic Spontaneous Urticaria; Generalized Myasthenia Gravis …Feb 2027
Guangzhou Lupeng Pharmaceutical CompanyRocbrutinib (LP-168)
BTK inhibitor
BTKPhase 3Mantle Cell Lymphoma; Mantle Cell Lymphoma (MCL); Diffuse Large B-Cell Lymphoma (DLBCL); Relapsing-remitting Multiple Sclerosis (RRMS) …Mar 2027
Ono PharmaceuticalTirabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Pemphigus; Relapsed/Refractory Primary Central Nervous System Lymphoma; Refractory Primary Central Nervous System Lymphoma; Primary Central Nervous System LymphomaMar 2027
Eli LillyPirtobrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; Lymphoma, Mantle-Cell; Richter Syndrome; Mantle Cell Lymphoma …May 2027
RocheFenebrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Relapsing Multiple Sclerosis; Multiple Sclerosis, Primary ProgressiveJun 2027
Beijing InnoCare Pharma TechOrelabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Relapsed/Refractory Marginal Zone Lymphoma; Hematologic Malignancies; Part 1:r/r B-cell Malignancies; OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma …Aug 2028
SanofiTolebrutinib (SAR442168)
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Relapsing Multiple SclerosisApr 2029
Zenas BioPharma (USA)Orelabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Secondary Progressive Multiple Sclerosis; Multiple Sclerosis (MS) Primary ProgressiveJun 2030
Zhejiang Cancer HospitalZebutinib
Bruton's tyrosine kinase (BTK) inhibitor
BTKPhase 2Rituximab, Lenalidomide, Zebutinib ,Mantle Cell LymphomaDec 2026
NOBO MedicinePoseltinib (NB02)
Tyrosine-protein kinase BTK inhibitor
BTKPhase 2Primary CNS Lymphoma (PCNSL); Non Hodgkin Lymphoma (NHL)Dec 2026
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityQL1706 (eparbrutinib)
Bruton's tyrosine kinase (BTK) inhibitor
BTKPhase 2Neoadjuvant ImmunotherapyMar 2027
Bin GuGecacitinib
Bruton's tyrosine kinase (BTK) inhibitor
BTKPhase 2aGVHDOct 2027
The First Affiliated Hospital with Nanjing Medical UniversitySonrotoclax
BTK inhibitor
BTKPhase 2CLL (Chronic Lymphocytic Leukemia)Dec 2027
Zhejiang Cancer HospitalThiotepa
BTK inhibitor
BTKPhase 2PirtobrutinibAug 2028
Shenzhen University General HospitalBugitinib
Bruton's tyrosine kinase (BTK) inhibitor
BTKPhase 2Acute Myeloid LeukemiaJun 2029
M.D. Anderson Cancer CenterBGB-16673
Bruton tyrosine kinase (BTK) degrader (PROTAC)
BTKPhase 2Chronic Lymphocytic Leukemia (CLL)Jul 2031
Carna BiosciencesAS-1763 (docirbrutinib)
BTK inhibitor
BTKPhase 1B-cell MalignancySep 2027
TransThera Sciences (Nanjing)TT-01488
non-covalent reversible BTK inhibitor
BTKPhase 1B-Cell MalignanciesOct 2028
MedolutionKeynatinib
BTK inhibitor
BTKPhase 1Lymphoma, B-CellOct 2032
Mingzhi ZhangObutinib
Bruton's tyrosine kinase (BTK) inhibitor
BTKPhase 1Newly Diagnosed Diffuse Large B-cell Lymphoma–

Conditions

Chronic Lymphocytic Leukemia (67) Mantle Cell Lymphoma (32) Mantle Cell Lymphoma (MCL) (12) Diffuse Large B-Cell Lymphoma (9) Marginal Zone Lymphoma (9) Waldenstrom Macroglobulinemia (9) Chronic Lymphocytic Leukemia (CLL) (8) Primary Central Nervous System Lymphoma (8) Relapsing Multiple Sclerosis (8) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (7) Follicular Lymphoma (7) Marginal Zone Lymphoma(MZL) (6)

Modalities

small molecule (22), mixed (6), antibody (2)

Companies

Sanofi (2) BeOne Medicines (2) Eli Lilly (2) Zhejiang Cancer Hospital (2) AstraZeneca (1) Guangzhou Lupeng Pharmaceutical Company (1) Zenas BioPharma (USA) (1) Carna Biosciences (1) Mingzhi Zhang (1) Merck & Co. (MSD) (1) Acerta Pharma (1) Beijing InnoCare Pharma Tech (1) Dizal Pharmaceuticals (1) Ono Pharmaceutical (1) Roche (1) Medolution (1) Nurix Therapeutics (1) Johnson & Johnson (Janssen) (1) Bin Gu (1) M.D. Anderson Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.